NHS Framework for the Midlands and East, Branded Medicines - Tranche B plus Cytokine Modulators and other Monoclonal Antibodies.

The NHS Commissioning Board (operating under the name of NHS England)

This public procurement record has 1 release in its history.

Award

23 Feb 2021 at 13:53

Summary of the contracting process

The NHS Commissioning Board, operating as NHS England, is conducting a tender for the "NHS Framework for the Midlands and East, Branded Medicines – Tranche B plus Cytokine Modulators and other Monoclonal Antibodies." This procurement process falls under the goods category, specifically targeting pharmaceutical products. The framework period spans from 1 March 2021 to 28 February 2023, with potential extensions. Notably, bids were submitted for various lots within the framework, showcasing an active competitive environment as of 23 February 2021.

This tender provides significant opportunities for businesses in the pharmaceutical sector, particularly those specialising in branded medicines, cytokine modulators, and monoclonal antibodies. Companies with expertise in producing these products, especially large or SME pharmaceutical firms, would be well-suited to compete, leveraging their capabilities to meet the NHS's evolving healthcare needs. Participants can also establish long-term relationships with NHS England, enhancing their market presence in the UK healthcare system.

How relevant is this notice?

Notice Title

NHS Framework for the Midlands and East, Branded Medicines - Tranche B plus Cytokine Modulators and other Monoclonal Antibodies.

Notice Description

CM/PHR/20/5591/01 - Midlands and East, Branded Medicines - Tranche B. Period of framework: 1 March 2021 to 28 February 2023 with an option to extend (at the Authority's discretion) for a period or periods up to a total of 24 monthsCM/PHR/20/5591/02 - Midlands and East Branded Medicines - Annual Tranche, Cytokine Modulators, other monoclonal antibodies Interleukin Inhibitors, JAK Inhibitors and medicines for Migraine and Asthma. Period of framework: 1 March 2021 to 28 February 2022 with an option to extend (at the Authority's discretion) for a period or periods up to a total of 12 monthsCM/PHR/20/5591/03 - Supply of Interleukin Inhibitors, JAK Inhibitors and medicines for Migraine and Asthma to Pan London. Period of framework: 1 March 2021 to 31 August 2021CM/PHR/20/5591/04 - Supply of Interleukin Inhibitors, JAK Inhibitors and medicines for Migraine and Asthma to South of England. Period of framework: 1 March 2021 to 31 August 2021

Lot Information

Lot 1: Midlands and East (MAE) Tranche B

CM/PHR/20/5591/01 - NHS Framework for the Midlands and East, Branded Medicines - Tranche B. Period of framework: 1 March 2021 to 28 February 2023 with an option to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents

Options: There will be an option to extend (at the Authority's discretion) for a period or periods up to a total of 24 months

Lot 2: Midlands and East Cytokine Modulators and other monoclonal antibodies

CM/PHR/20/5591/02 - NHS Framework for the Midlands and East Branded Medicines - Annual Tranche, Cytokine Modulators, other monoclonal antibodies Interleukin Inhibitors, JAK Inhibitors and medicines for Migraine and Asthma. Period of framework: 1 March 2021 to 28 February 2022 with an option to extend (at the Authority's discretion) for a period or periods up to a total of 12 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents

Options: There will be an option to extend (at the Authority's discretion) for a period or periods up to a total of 12 months

Lot 3: (LNW) - Interleukin Inhibitors, JAK Inhibitors, Migraine & Asthma

CM/PHR/20/5591/03 - NHS Framework agreement for the supply of Interleukin Inhibitors, JAK Inhibitors and medicines for Migraine and Asthma to Pan London. Period of framework: 1 March 2021 to 31 August 2021. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents

Lot 4: (SOFE) - Interleukin Inhibitors, JAK Inhibitors, Migraine & Asthma

CM/PHR/20/5591/04 - NHS Framework agreement for the supply of Interleukin Inhibitors, JAK Inhibitors and medicines for Migraine and Asthma to South of England. Period of framework: 1 March 2021 to 31 August 2021. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents

Publication & Lifecycle

Open Contracting ID
ocds-h6vhtk-029565
Publication Source
Find A Tender Service
Latest Notice
https://www.find-tender.service.gov.uk/Notice/003581-2021
Current Stage
Award
All Stages
Award

Procurement Classification

Notice Type
Award Notice
Procurement Type
Framework
Procurement Category
Goods
Procurement Method
Open
Procurement Method Details
Open procedure
Tender Suitability
Not specified
Awardee Scale
Large, SME

Common Procurement Vocabulary (CPV)

CPV Divisions

33 - Medical equipments, pharmaceuticals and personal care products


CPV Codes

33600000 - Pharmaceutical products

Notice Value(s)

Tender Value
Not specified
Lots Value
Not specified
Awards Value
Not specified
Contracts Value
£1

Notice Dates

Publication Date
23 Feb 20215 years ago
Submission Deadline
Not specified
Future Notice Date
Not specified
Award Date
Not specified
Contract Period
Not specified - Not specified
Recurrence
Not specified

Notice Status

Tender Status
Complete
Lots Status
Cancelled
Awards Status
Active
Contracts Status
Active

Contracting Authority (Buyer)

Main Buyer
The NHS Commissioning Board (operating under the name of NHS England)
Contact Name
Available with D3 Tenders Premium →
Contact Email
Available with D3 Tenders Premium →
Contact Phone
Available with D3 Tenders Premium →

Buyer Location

Locality
RUNCORN
Postcode
WA7 2ES
Postcode Area
Warrington
Country
England

Major Region (ITL 1)
TLD North West (England)
Basic Region (ITL 2)
TLD7 Merseyside
Small Region (ITL 3)
TLD71 East Merseyside
Delivery Location
Not specified

Local Authority
Halton
Electoral Ward
Halton Lea
Westminster Constituency
Runcorn and Helsby

Supplier Information

Number of Suppliers
37
Supplier Names

Accord-UK Ltd

Aventis Pharma ltd

Bayer Plc

Biogen

Bristol Myers Squibb

Celltrion Healthcare United Kingdom Limited

CST Pharma Limited

Daiichi Sankyo UK Ltd

Day Lewis Medical Ltd

Dr.Reddy's Laboratories (UK) Limited

Eli Lilly & Company Ltd

LEO Pharma

Ferring Pharmaceuticals Ltd

Gilead Sciences Limited

Ipsen

Merck Serono Limited

Merck Sharpe & Dohme (UK) Limited

Mylan

Napp Pharmaceuticals Ltd

Novo Nordisk

Roche Products Ltd

ROVI Biotech Ltd

Novartis Pharmaceuticals UK Ltd

Pfizer Ltd

Sandoz Ltd

Techdow Pharma England Ltd

Takeda UK Ltd

Teva UK Limited

UL Global Pharma

AstraZeneca

Amgen Ltd

Gedeon Richter UK Ltd

Thornton and Ross Ltd

UCB Pharma Ltd

Janssen-Cilag Ltd

Organon Pharmaceuticals UK Ltd

Sobi (Swedish Orphan Biovitrum Ltd)

Open Contracting Data Standard (OCDS)

View full OCDS Record for this contracting process

JSON Markdown

The Open Contracting Data Standard (OCDS) is a framework designed to increase transparency and access to public procurement data in the public sector. It is widely used by governments and organisations worldwide to report on procurement processes and contracts.

Loading OCDS record...